Are You Buying Gilead Sciences, Inc. for the Wrong Reason?

Are You Buying Gilead Sciences, Inc. for the Wrong Reason?

Gilead Sciences (NASDAQ: GILD) is up about 12% over the last week or so since Novartis (NYSE: NVS) got its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah approved by the FDA.

That's just ridiculous for a couple of reasons:

The best-case scenario for Gilead wasn't an FDA approval of Kymriah, but a rejection based on some reason other than the fact that it was a CAR-T therapy.

Continue reading

Source: Fool.com